focus -WSS

focus

author：knowledge 2025-09-28 01:39:07 - browse：283

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Alzheimer's risk factor APOE4 may be a distinct form of the disease

leisure time

WSS

Watch the official trailer for 'Ahsoka' series

Study: Black kids more likely to die after surgery than white kids

Companies helping big Covid

Sickle cell gene therapy cures need to be accessible in Africa

Sickle cell gene therapy cures need to be accessible in Africa

Young boy dies in trial for Pfizer Duchenne gene therapy

leisure time

focus

hotspot

How one medical school became remarkably diverse

Florida Supreme Court upholds state's abortion ban

Affirmative action in medical school literally saved lives

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

After affirmative action ruling, medical educators look to 'holistic review'

Drug companies' payments and gifts affect physicians' prescribing

Drug repurposing or repositioning? The language matters

Digital health funding stays low as a new reality sets in

knowledge

Bird flu reported in person exposed to presumably infected cattle

Digital health funding stays low as a new reality sets in

How are insurers handling Leqembi and related scans?

Superbugs, antibiotic resistance get scrutiny in congress

Vermont grapples with historic flooding as more rainstorms head for Northeast

First Opinion on colorectal cancer screening: letter and response

leisure time

focus

knowledge

hotspot